-
Module 2_BCMA-Targeted CAR T-cells
24:20
-
Module 1_Introduction and Rationale for Targeting BCMA on MM Cells
10:45
-
Module 3_BCMA-Targeted Antibody-Drug Conjugates (ADCs)
9:40
-
Module 4_BCMA-Targeted Bispecifics
22:12
-
Virtual Challenging Case Clinic: Multiple Myeloma_Updates from ASH_Peter Voorhees, MD
56:33
-
Virtual Challenging Case Clinic: Multiple Myeloma_Optimal Induction and Maintenance Therapies_Amrita Krishnan, MD
47:14
-
New Approvals and Advanced Targets in MM_Joshua Richter, MD
49:01
-
Madhav Dhodapkar, MBBS; Emory University Winship Cancer Institute; #DDHO2022
12:52
-
Sagar Lonial, MD, FACP; Emory University Winship Cancer Institute; #DDHO2022
23:12
-
Jonathan Kaufman, MD; Emory University Winship Cancer Institute; #DDHO2022
17:41
-
Craig Hofmeister, MD, MPH; Emory University Winship Cancer Institute; #DDHO2022
10:06
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company